Skip to main content

Market Overview

IDT Biologika To Make J&J's COVID-19 Vaccine Using Takeda's Manufacturing Capacity


Japan’s Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed an agreement with Germany-based contract manufacturer IDT Biologika GmbH to make Johnson & Johnson’s (NYSE: JNJ) single-dose COVID-19 vaccine.

  • Under the contract, the capacity at IDT’s Dessau site, previously reserved to make Takeda’s dengue vaccine candidate, will be used to make J&J’s COVID-19 vaccine for worldwide distribution.
  • After three months, the capacity will be returned to Takeda to resume manufacturing for its dengue vaccine’s planned launch.
  • This year, Merck & Co (NYSE: MRK) and Sanofi SA (NASDAQ: SNY) agreed to help make J&J’s vaccine.
  • Takeda is handling the Japanese approval process, import, and distribution of coronavirus vaccines from Moderna Inc (NASDAQ: MRNA) and Novavax Inc (NASDAQ: NVAX).
  • IDT is already producing AstraZeneca Plc’s (NASDAQ: AZN) COVID-19 vaccine.
  • Price Action: TAK shares are trading 2.25% higher at 18.85, and JNJ shares are up 0.41% at $160.25 in market trading hours on the last check Monday.

Related Articles (JNJ + TAK)

View Comments and Join the Discussion!

Posted-In: COVID-19 VaccineBiotech News Health Care Contracts FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at